Table 2.
The efficacy of apatinib in different trials
| Trial | Placebo
|
Apatinib
|
|||
|---|---|---|---|---|---|
| Median OS (months) | Median PFS (months) | Regimen | Median OS (months) | Median PFS (months) | |
| Gastric cancer | |||||
| Phase II40 | 2.50 | 1.40 | 850 mg/day | 4.83 | 3.67 |
| 425 mg/bid | 4.27 | 3.2 | |||
| Phase III41 | 4.7 | 1.8 | 850 mg/day | 6.5 | 2.6 |
| Breast cancer | |||||
| TNBC19 | 500 mg/day | 10.6 | 3.3 | ||
| MBC45 | 500 mg/day | 10.3 | 4.9 | ||
| Lung cancer | |||||
| NSCLC20 | 500 mg/day | 6.0 | 4.2 | ||
| EGFR wild type52 | 250–500 mg/day | 4.4 | |||
| Esophageal squamous cell carcinoma21 | 500 mg/day | 7.0 | 3.8 | ||
Abbreviations: bid, twice daily; EGFR, epidermal growth factor receptor; MBC, metastatic breast cancer; NSCLC, non-small-cell lung cancer; OS, overall survival; PFS, progression-free survival; TNBC, triple-negative breast cancer.